tirzepatide and keto In adults with obesity but not diabetes, leads to significantly greater weight loss than semaglutide over 72 weeks, nearly double the patients on tirzepatide meet the 25% weight-loss target. http://ms.spr.ly/6183SkuIL What to Eat on a

Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist used for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of: 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, dyslipidemia, obstructive sleep apnea or cardiovascular disease)

For most people, the answer is no

This is the trial that will carry the weight-management NDA

Finerenone and other future therapeutic options for Alport syndrome

After the initial dose escalation phase (weeks 4-10), side effects dropped dramatically